Professional
Added to YB: 2024-10-18
Pitch date: 2024-09-30
NVO [bullish]
Novo Nordisk A/S
-67.73%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 113.64
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
N/A
Polen Global Growth Portfolio Holding: Novo Nordisk A/S
NVO: Mixed safety data in midstage trial for new oral weight loss drug caused weakness. Significant weight loss vs placebo, but limited gains at higher doses with mild-moderate side effects. Market concerns over commercial viability & competition from Eli Lilly. Key next-gen drugs promising; efforts to increase production for high demand.
Read full article (1 min)